{"id":58069,"date":"2025-08-17T18:31:42","date_gmt":"2025-08-17T22:31:42","guid":{"rendered":"https:\/\/bnonews.com\/?p=58069"},"modified":"2025-08-17T18:50:43","modified_gmt":"2025-08-17T22:50:43","slug":"how-dendritic-cell-immunotherapy-works-insights-from-german-cancer-centers","status":"publish","type":"post","link":"https:\/\/bnonews.com\/index.php\/2025\/08\/how-dendritic-cell-immunotherapy-works-insights-from-german-cancer-centers\/","title":{"rendered":"How Dendritic Cell Immunotherapy Works: Insights from German Cancer Centers"},"content":{"rendered":"\n

Dendritic cell immunotherapy is an innovative and highly personalized cancer treatment that uses the body\u2019s own immune system to target tumors. Unlike chemotherapy or radiation, which affect both healthy and cancerous cells, dendritic cell therapy<\/a> aims to activate immune responses specifically against cancer cells. This precision makes it especially appealing to patients seeking effective treatments with fewer side effects.<\/p>\n\n\n\n

The therapy is based on dendritic cells – special immune cells responsible for recognizing foreign or abnormal substances and alerting T cells to destroy them. By collecting these cells from the patient, training them in a laboratory to recognize tumor antigens, and then reintroducing them, doctors can \u201cteach\u201d the immune system to fight cancer more effectively.<\/p>\n\n\n\n

How Dendritic Cell Therapy Is Performed in Germany<\/strong><\/h2>\n\n\n\n

Patient Assessment and Planning<\/strong><\/h3>\n\n\n\n

International patients begin with a medical evaluation, during which oncologists review the cancer diagnosis, treatment history, and eligibility for the therapy.<\/p>\n\n\n\n

Cell Collection (Leukapheresis)<\/strong><\/h3>\n\n\n\n

In a specialized procedure called leukapheresis, white blood cells are separated from the patient\u2019s blood. These cells contain monocytes, which will be transformed into dendritic cells in the laboratory.<\/p>\n\n\n\n

Laboratory Preparation<\/strong><\/h3>\n\n\n\n

Using advanced GMP-compliant facilities, monocytes are cultured with growth factors to develop into dendritic cells. Tumor antigens – either from the patient\u2019s own tumor tissue or known cancer-specific proteins – are introduced so the cells can \u201clearn\u201d to recognize the cancer.<\/p>\n\n\n\n

Reintroduction to the Patient<\/strong><\/h3>\n\n\n\n

Once matured, the dendritic cells are injected back into the patient, typically over several sessions. These cells then travel to lymph nodes, where they activate T cells to seek and destroy cancer cells carrying the same antigens.<\/p>\n\n\n\n

Follow-up and Monitoring<\/strong><\/h3>\n\n\n\n

Patients are closely monitored with immune system tests and imaging to track response and adjust treatment plans if necessary.<\/p>\n\n\n\n

Germany\u2019s Leading Role and the Expertise of Dr. Thomas Ne\u00dfelhut in Duderstadt<\/strong><\/h2>\n\n\n\n

Germany stands out globally due to its strict regulatory environment, advanced biotechnology infrastructure, and experienced immunotherapy practitioners. One provider is the Practice Group for Cell Therapy in Duderstadt, headed by Dr. Thomas Ne\u00dfelhut<\/a>, in the field of tumor immunology. With over four decades of experience in developing autologous tumor vaccines and heading laboratories focused on dendritic cell therapy, Dr. Ne\u00dfelhut\u2019s clinic operates a fully licensed GMP laboratory that manufactures personalized dendritic cell vaccines under strict quality controls.<\/p>\n\n\n\n

According to the clinic\u2019s official information, they are committed to offering \u201call sensible therapeutic options\u201d within a holistic treatment framework, combining advances in immunology with conventional cancer treatments while maintaining rigorous safety and quality standards. Patients undergo individual treatment plans using patient-specific vaccines crafted in their laboratory, regularly audited by regulatory authorities.<\/p>\n\n\n\n

Treatment Efficiency: What the Data Shows<\/strong><\/h2>\n\n\n\n

Across peer-reviewed studies, the strongest efficacy signal for dendritic cell (DC) immunotherapy consistently shows up in immune-activation metrics rather than raw tumor shrinkage: when DC vaccines are administered intradermally, antigen-specific T-cell responses have reached ~80% of treated patients in combined melanoma and prostate cancer cohorts, markedly higher than with intranasal dosing in the same trials (\u224842%)\u2014a difference that underscores how delivery route and vaccine engineering shape outcomes.<\/p>\n\n\n\n

Clinically, large datasets in glioblastoma (GBM) with DCVax-L don\u2019t hit 80% objective responses (which remain rare in GBM overall), but they do show a statistically significant survival advantage that widens over time\u2014for example, 13.0% vs 5.7% alive at 60 months for DCVax-L versus external controls, and 19.3 months vs 16.5 months median overall survival in newly diagnosed GBM\u2014while keeping severe treatment-related toxicities low (only ~2% grade 3\/4 events in a 331-patient phase III analysis).<\/p>\n\n\n\n

Operationally, modern German-style manufacturing pipelines report 97\u2013100% success in turning a patient\u2019s leukapheresis into a final DC vaccine product\u2014critical for international travelers with tight timelines\u2014and these vaccines reliably induce biologic responses that correlate with better long-term disease control in multiple solid-tumor settings. Put together, the most reproducible \u201c>80%\u201d efficacy readout today is immunologic response (T-cell activation) with optimized intradermal DC vaccination, supported by improving survival tails in GBM and high manufacturing reliability and safety across programs – giving patients a realistic blend of strong immune engagement, manageable toxicity, and growing evidence of durable clinical benefit.<\/p>\n\n\n\n

Booking Your Treatment Through AiroMedical<\/strong><\/h2>\n\n\n\n

For international patients, arranging medical care in another country can be complex. AiroMedical is an international medical booking platform<\/a> that simplifies the process of accessing dendritic cell therapy in Germany.<\/p>\n\n\n\n

Through AiroMedical, patients can:<\/p>\n\n\n\n